Metabolic Side Effect Prediction via Transporter Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug therapies face challenges due to variability in human metabolism, leading to sub-therapeutic or toxic drug levels, as standardized doses do not account for individual differences in drug transporters, such as OATs and OCTs, which interact with many medications, resulting in morbidity and mortality.
Innovation Solution
A combined systems biology and computational chemistry approach is used to identify and predict the impact of drugs on transporter-mediated metabolism by analyzing metabolites affected by transporter deletion, constructing metabolic networks, and determining pharmacophores associated with drug transporters, allowing for personalized drug therapy and monitoring of metabolic side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If standardized doses of medications are used, then drug administration is simplified, but drug levels range from sub-therapeutic to toxic due to individual variability in metabolism and excretion
Solution Approach 1:
The patent applies parameter changes by moving from fixed standardized doses to personalized dosing regimens based on individual metabolic profiles. Metabolic parameters such as transporter expression levels and enzyme activity are measured to adjust drug dosing, transforming the approach from one-size-fits-all to customized dosing that accounts for inter-individual variability in drug metabolism and excretion.
Solution Approach 2:
The patent replaces the mechanical system of standardized dosing with a systems biology approach that integrates multiple data types (genomic, transcriptomic, proteomic, metabolomic) to predict individual drug responses. This substitution allows for more accurate prediction of drug levels and metabolic side effects by considering the complex biological system rather than relying on fixed dosing protocols.
2Measurement precision
If multiple drug transporters are considered in metabolism, then prediction accuracy of metabolic side effects is improved, but complexity of analysis increases
Solution Approach 1:
The patent applies segmentation by dividing the complex metabolic analysis into separate, manageable modules. Each module handles specific aspects such as transporter identification, metabolite prediction, pathway analysis, and side effect assessment. This modular approach allows the system to process multiple drug transporters and their interactions with various metabolites in an organized manner, reducing overall analysis complexity while maintaining high prediction accuracy.
Solution Approach 2:
The patent implements universality through a multi-functional integrated platform that can analyze multiple drug transporters (OATs, OCTs, and other SLC/ABC family members), predict metabolite interactions, identify disease-associated pathways, and assess metabolic side effects. This single system performs multiple functions that would otherwise require separate analyses, thereby improving prediction accuracy without proportionally increasing complexity.
3Measurement precision
If comprehensive metabolite analysis is performed, then identification of drug transporter-associated pathways is improved, but time required for analysis increases
Solution Approach 1:
The patent applies preliminary action by pre-establishing metabolic pathways and transporter interactions through database curation and computational modeling before actual analysis. Pre-computed transporter-substrate relationships, metabolic networks, and pathway maps serve as ready-to-use frameworks that accelerate real-time analysis. This preliminary preparation allows the system to quickly identify drug transporter-associated pathways without performing exhaustive de novo analysis, thereby reducing time requirements while maintaining comprehensive pathway identification.
Data Source
AI summary
Provided are drug-transport metabolomics profile assessments and therapies.